Loading...
Many new agents from novel drug classes are now available through expanded access and are expected to gain FDA approval within the next year. Having so many new agents available at the same time means that clinicians can finally construct salvage regimens that maximize the likelihood of full virologic suppression while minimizing further resistance. Still, resistance to these new agents is inevitable, as indicated by many presentations at this year’s International HIV Drug Resistance Workshop, which took place in mid-June in Barbados. The findings described herein are all from industry-supported studies.
Two CCR5 antagonists are currently in the late stages of clinical development: Maraviroc is available through expanded-acce…